Emerging therapies for liver fibrosis

Area of Science:

• Hepatology
• Fibrosis Research
• Pharmacology

Background:

• Liver fibrosis, progressing to cirrhosis, impairs liver function and causes significant mortality.
• Current treatments like transplantation have limitations, necessitating new antifibrotic strategies.
• Liver fibrosis is a dynamic, bidirectional process, with potential for reversal even in advanced stages.

Purpose of the Study:

• To review the molecular mechanisms underlying the bidirectional nature of liver fibrosis.
• To highlight emerging antifibrotic agents and their therapeutic potential.
• To underscore the need for pharmacological interventions targeting the fibrotic process.

Main Methods:

• Review of current laboratory and clinical studies on liver fibrosis mechanisms.
• Analysis of molecular pathways involved in fibrosis progression and reversal.
• Discussion of emerging antifibrotic drug candidates.

Main Results:

• Liver fibrosis is a reversible process, even in advanced stages like cirrhosis.
• Understanding the molecular basis of bidirectionality is key to developing effective antifibrotic therapies.
• Several novel antifibrotic agents are under investigation.

Conclusions:

• Advanced liver fibrosis and cirrhosis may be reversible.
• Targeting the molecular mechanisms of fibrosis bidirectionality is crucial for effective treatment.
• Further research into emerging antifibrotic agents is warranted to address the global burden of liver disease.